The laboratory analyzes each sample individually (single-sample testing) and not by pooling (several samples together).
Molecular tests are indicated for the symptomatic phase of the disease, as they determine if someone has been infected with the virus now, but do not show if anyone was infected in the past. Depending on the doctors’ recommendations, the molecular test may be performed shortly after the symptoms onset and may be repeated in a couple of days.
This method is considered the ‘gold standard’ examination since it can confirm that the virus is actually present in the body. It is recommended for everyone, when the active disease must be documented, regardless of whether it is symptomatic or not.
More reliable results are obtained after the fourth day of transmission of the infection. The method used to detect the genetic material of the virus and therefore to confirm its presence in the test material is called reverse transcriptase polymerase chain reaction (RT-PCR) assay and the specimen used is nasopharyngeal, oropharyngeal smear or combined nasopharyngeal plus oropharyngeal smear for greater sensitivity.
Molecular PCR Τesting: 47€*
*Valid from January 6, 2022 based on Ministerial Decision 657/2022 – Government Gazette 2 / Β / 4-1-2022
|Coronavirus detection test with molecular method PCR||35€|
|Sampling for the coronavirus detection test with molecular method PCR||12€|
Rapid testing is recommended at this stage of the pandemic, wherever rapid detection of positive cases is necessary in order to stop the transmission of COVID-19 disease.
It is suitable for symptomatic people to determine if they are infected with the virus or not. It is also suitable for asymptomatic people, as long as they meet the relevant epidemiological criteria.
Coronavirus Antigen detection test (Rapid test): 10€
|Coronavirus antigen detection test by the rapid test method (COVID-19 Ag Rapid test)||10€|
It is recommended by experts as the test of choice for the epidemiological surveillance of large groups as well as in places of mass gatherings (social events, large companies, factories, clubs, school communities, sports events, etc.) as it can contribute to the immediate identification and isolation of positive cases.
In Bioiatriki, the rapid detection system of ABBOTT Diagnostics is used for the analysis, with 93.3% sensitivity and 99.4% specificity, while the examination is performed painlessly, with a nasopharyngeal smear specimen.
In Bioiatriki Group laboratories, we carry out a semi-quantitative detection of antibodies IgA, IgM and IgG. These antibodies are produced by the infected person as a defense against the new coronavirus SARS-CoV-2.
IgM antibodies are produced by the immune system fairly quickly and provide first-line defense during active infection. IgA antibodies show a recent infection with the virus and remain stable for longer than IgM. IgG antibodies are produced later on during the infection, remain stable for a long time and their detection indicates a previous contact of the person with the virus, while they are directly related to the development of immunity to the virus.
In the current phase of the pandemic, in addition to the qualitative detection of antibodies, the quantification of IgG antibodies is particularly important, since they are the antibodies that «build» the body’s long-term immunity against the coronavirus. Measuring these antibodies provides important information about our body’s ability to defend itself and its level of immunity to SARS-CoV-2.
Of particular value is the measurement of anti-spike IgG antibodies, which act against the apical protein S of the coronavirus through which the virus attaches to and enters human cells. Quantification of anti-spike IgG antibodies is useful for assessing post-vaccination immunization efficacy against SARS-CoV-2.
The detection of antibodies is performed by blood sampling, and all the necessary safety measures for the examinees and the employees (healthcare personnel) are applied.
Αll Covid-19 tests are performed at Athens Bioclinic and Thessaloniki
and in selected Diagnostic Centers of the BIOATRIKI Group.